{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:04:51Z","timestamp":1787061891384,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      We evaluated the efficacy and safety of amifampridine phosphate (Firdapse\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) for symptomatic treatment in Lambert\u2010Eaton myasthenic syndrome (LEMS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Phase 3, randomized, double\u2010blind, study. Patients were treated initially with amifampridine phosphate for 7\u201391 days, followed by randomization to continue amifampridine phosphate for 14 days or placebo (7\u2010day taper, 7\u2010day placebo). The primary efficacy endpoints were changes from baseline at day 14 in Quantitative Myasthenia Gravis and Subject Global Impression scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The coprimary efficacy end points and 1 of the secondary efficacy end points were met, showing a significant benefit of aminfampridine phosphate over placebo at Day 14. All 5 primary, secondary, and tertiary endpoints achieved statistical significance at Day 8. Amifampridine phosphate was well tolerated; the most common adverse events were oral and digital paresthesias, nausea, and headache.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study provides Class I evidence of efficacy of amifampridine phosphate as a symptomatic treatment for LEMS.\n                      <jats:italic>Muscle Nerve<\/jats:italic>\n                      <jats:bold>53<\/jats:bold>\n                      : 717\u2013725, 2016\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mus.25070","type":"journal-article","created":{"date-parts":[[2016,2,6]],"date-time":"2016-02-06T21:48:46Z","timestamp":1454795326000},"page":"717-725","source":"Crossref","is-referenced-by-count":58,"title":["Amifampridine phosphate (Firdapse\n                    <sup>\u00ae<\/sup>\n                    ) is effective and safe in a phase 3 clinical trial in LEMS"],"prefix":"10.1002","volume":"53","author":[{"given":"Shin J","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Neurology University of Alabama at Birmingham Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Shcherbakova","sequence":"additional","affiliation":[{"name":"Research Center of Neurology Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kostera\u2010Pruszczyk","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alsharabati","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Alabama at Birmingham Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Dimachkie","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Munoz","family":"Blanco","sequence":"additional","affiliation":[{"name":"Gregorio Maranon Hospital Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brannagan","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Lavrni\u0107","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Clinic of Neurology Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vial","sequence":"additional","affiliation":[{"name":"Hospital of Lyon, ENMG Service and Neuromuscular Pathology Hospital Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Charite Universitatsmedizin Berlin\u2010NeuroCure Clinical Research Center Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Komoly","sequence":"additional","affiliation":[{"name":"University of P\u00e9cs, Department of Neurology P\u00e9cs Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[{"name":"Ludwig\u2010Maximilians\u2010University Munich Friedrich\u2010Baur\u2010Institute Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaraswamy","family":"Sivakumar","sequence":"additional","affiliation":[{"name":"Neuromuscular Research Center Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen","family":"So","sequence":"additional","affiliation":[{"name":"Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LEMS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/111.3.577"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.065"},{"issue":"1","key":"e_1_2_7_4_1","first-page":"5","article-title":"The emerging diversity of neuromuscular junction disorders","volume":"26","author":"Newsom\u2010Davis J","year":"2007","journal-title":"Acta Myol"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1971.tb30750.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.4.848"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.17925\/USN.2014.10.02.i"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01249.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.06.007"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20389"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506013322203"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"41","author":"Barohn RJ","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60442-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.5.871"},{"key":"e_1_2_7_18_1","unstructured":"Catalyst Pharmaceutical Partners. A Phase 3 Multicenter Double\u2010blind Placebo\u2010controlled Randomized Discontinuation Study Followed by an Open\u2010label Extension Period to Evaluate the Efficacy and Safety of Amifampridine phosphate (3 4\u2010Diaminopyridine Phosphate) in Patients with Lambert\u2010Eaton Myasthenic Syndrome (LEMS). Clinical Study Protocol page 74. Catalyst Pharmaceutical Partners Inc. Coral Gables Florida"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22949.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21422"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.603"},{"issue":"2","key":"e_1_2_7_22_1","first-page":"CD003279","article-title":"Treatment for Lambert\u2010Eaton myasthenic syndrome","author":"Keogh M","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003745209"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","article-title":"Effects of 4\u2010aminopyridine and 3,4\u2010diaminopyridine on transmitter release at the neuromuscular junction","volume":"227","author":"Thomsen RH.","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.46.7.684"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1993.tb04205.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912073212303"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.35"},{"key":"e_1_2_7_29_1","article-title":"The DAPPER study team. Results from the dapper study: inpatient double blind, placebo\u2010controlled withdrawal study of 3,4 diaminopyridine base (3,4\u2010DAP) in subjects with Lambert\u2010Eaton myasthenic syndrome. 2015 abstract","author":"Sanders D","year":"2015","journal-title":"Muscle Nerve"},{"key":"e_1_2_7_30_1","unstructured":"Catalyst Pharmaceutical Partners Reports Positive Cardiac Safety Results of Its Phase 3 Product Firdapse Tablets. In: GlobeNewsWise. January 8 2014. Available athttp:\/\/globenewswire.com\/news-release\/2014\/01\/08\/601054\/10063346\/en\/Catalyst-Pharmaceutical-Partners-Reports-Positive-Cardiac-Safety-Results-of-Its-Phase-3-Product-Firdapse-Tablets.html. Accessed 2015 May 22."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199912)22:12<1727::AID-MUS19>3.0.CO;2-K"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25070","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.25070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T05:51:02Z","timestamp":1748757062000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.25070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/mus.25070"],"URL":"https:\/\/doi.org\/10.1002\/mus.25070","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}